

## Overview

### Useful For

Providing a genetic evaluation for patients with a personal or family history suggestive of a hereditary form of dilated cardiomyopathy or left ventricular noncompaction

Establishing a diagnosis of a hereditary form dilated cardiomyopathy or left ventricular noncompaction

### Genetics Test Information

This test utilizes next-generation sequencing to detect single nucleotide and copy number variants in 63 genes associated with hereditary forms of dilated cardiomyopathy and left ventricular noncompaction: *ABCC9, ACAD9, ACADVL, ACTC1, ACTN2, ALMS1, ALPK3, BAG3, CDH2, CPT2, CRYAB, CSRP3, DES, DMD, DNAJC19, DOLK, DSC2, DSG2, DSP, EMD, FKRP, FTKN, FLNC, GAA, GLA, HCN4, JPH2, JUP, LAMP2, LMNA, MYBPC3, MYH7, MYLK3, MYPN, NEXN, NKX2-5, PCCA, PCCB, PKP2, PLN, PPA2, PPCS, PRDM16, RAF1, RBM20, RYR2, SCN5A, SGCD, SHOC2, SLC22A5, TAZ (TAFazzin), TBX20, TCAP, TMEM43, TMEM70, TNNC1, TNNI3, TNNI3K, TNNT2, TPM1, TTN, TTR, and VCL*. See [Targeted Genes and Methodology Details for Dilated Cardiomyopathy and Left Ventricular Noncompaction Cardiomyopathy Gene Panel](#) and Method Description for additional details.

Identification of a disease-causing variant may assist with diagnosis, prognosis, clinical management, familial screening, and genetic counseling for hereditary forms of dilated cardiomyopathy and left ventricular noncompaction.

[Prior Authorization](#) is available for this assay.

### Special Instructions

- [Informed Consent for Genetic Testing](#)
- [Hereditary Cardiomyopathies and Arrhythmias: Patient Information](#)
- [Informed Consent for Genetic Testing \(Spanish\)](#)
- [Targeted Genes and Methodology Details for Dilated Cardiomyopathy and Left Ventricular Noncompaction Cardiomyopathy Gene Panel](#)
- [Dilated Cardiomyopathy and Left Ventricular Noncompaction Cardiomyopathy Gene Panel\) Prior Authorization Ordering Instructions](#)

### Method Name

Sequence Capture and Targeted Next-Generation Sequencing followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing.

### NY State Available

Yes

## Specimen

**Specimen Type**

Varies

**Ordering Guidance**

This test is intended for genetic screening for and diagnosis of dilated cardiomyopathy or left ventricular noncompaction.

For comprehensive cardiomyopathy genetic testing, order CCMGG / Comprehensive Cardiomyopathy Gene Panel, Varies.

Customization of this panel and single gene analysis for any gene present on this panel are available. For more information see CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.

Targeted testing for familial variants (also called site-specific or known mutations testing) is available for the genes on this panel. See FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.

**Shipping Instructions**

Specimen preferred to arrive within 96 hours of collection.

**Necessary Information**

Prior Authorization is available, **but not required**, for this test. If proceeding with the prior authorization process, submit the required form with the specimen.

**Specimen Required**

**Patient Preparation:** A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

**Specimen Type:** Whole blood

**Container/Tube:**

**Preferred:** Lavender top (EDTA) or yellow top (ACD)

**Acceptable:** Any anticoagulant

**Specimen Volume:** 3 mL

**Collection Instructions:**

1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. **Do not aliquot.**

**Specimen Stability Information:** Ambient (preferred)/Refrigerated

**Forms**

**1. New York Clients-Informed consent is required.** Document on the request form or electronic order that a copy is on file. The following documents are available:

-[Informed Consent for Genetic Testing \(T576\)](#)

-[Informed Consent for Genetic Testing \(Spanish\) \(T826\)](#)

---

2. [Hereditary Cardiomyopathies and Arrhythmias: Patient Information](#)
3. [Dilated Cardiomyopathy/LVNC Panel \(DCLNG\) Prior Authorization Ordering Instructions](#)
4. [If not ordering electronically, complete, print, and send a Cardiovascular Test Request Form \(T724\) with the specimen.](#)

**Specimen Minimum Volume**

1 mL

**Reject Due To**

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability

**Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Varies	Varies		

**Clinical & Interpretive****Clinical Information**

The cardiomyopathies are a group of disorders characterized by disease of the heart muscle. Cardiomyopathy can be caused by inherited, genetic factors or by nongenetic (acquired) causes such as infection and inflammation.(1) When the presence or severity of the cardiomyopathy observed in a patient cannot be explained by acquired causes, genetic testing for the inherited forms of cardiomyopathy may be considered.

Hereditary forms of dilated cardiomyopathy (DCM) are characterized by ventricular dilation with reduced cardiac performance in the absence of other cardiac or systemic causes that may cause dilation of the heart muscle, such as hypertension and ischemic heart disease. The incidence of DCM in the general population is approximately 1 in 2500 (1), and it is estimated that approximately 50% of cases can be attributed to a genetic etiology.(1) Hereditary forms of DCM are most often caused by genes encoding proteins of the cardiac cytoskeleton and sarcomere.

Left ventricular noncompaction (LVNC) is characterized by prominent trabeculations of the left ventricle with trabecular recesses extending into the ventricular cavity. The incidence of LVNC in the general population is estimated to be 1 in 5000.(2) It is currently unclear if LVNC represents a genetically distinct form of cardiomyopathy, as many familial cases of LVNC have been linked to the same genes associated with other forms of hereditary cardiomyopathies, and many affected individuals also meet diagnostic criteria for DCM or hypertrophic cardiomyopathy.(2,3)

The clinical presentation of DCM and LVNC can be variable, even within the same family. DCM and LVNC can be apparently asymptomatic in some individuals but can cause sudden, life-threatening arrhythmias, increasing the risk of sudden cardiac death. In addition, some patients with primary hypertrophic cardiomyopathy or arrhythmogenic cardiomyopathy may eventually develop dilated ventricles, resembling DCM in later stages of disease progression.(1) DCM may also be a feature of an underlying systemic disorder such as amyloidoses and musculoskeletal conditions.(1)

Hereditary forms of DCM and LVNC can follow an autosomal dominant, autosomal recessive, and X-linked patterns of

---

inheritance. Mitochondrial inheritance is also possible, however, genes associated with mitochondrial inheritance of DCM and LNVC are not assessed on this panel.

**Reference Values**

An interpretive report will be provided.

**Interpretation**

All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations.(4) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

**Cautions****Clinical Correlations:**

Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

If testing was performed because of a clinically significant family history, it is often useful to first test an affected family member. Detection of a reportable variant in an affected family member would allow for more informative testing of at-risk individuals.

To discuss the availability of additional testing options or for assistance in the interpretation of these results, contact the Mayo Clinic Laboratories genetic counselors at 800-533-1710.

**Technical Limitations:**

Next-generation sequencing may not detect all types of genomic variants. In rare cases, false-negative or false-positive results may occur. The depth of coverage may be variable for some target regions; assay performance below the minimum acceptable criteria or for failed regions will be noted. Given these limitations, negative results do not rule out the diagnosis of a genetic disorder. If a specific clinical disorder is suspected, evaluation by alternative methods can be considered.

There may be regions of genes that cannot be effectively evaluated by sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high guanine-cytosine (GC) content, and repetitive sequences. Confirmation of select reportable variants will be performed by alternate methodologies based on internal laboratory criteria.

This test is validated to detect 95% of deletions up to 75 base pairs (bp) and insertions up to 47 bp. Deletions-insertions (delins) of 40 or more bp, including mobile element insertions, may be less reliably detected than smaller delins.

**Deletion/Duplication Analysis:**

This analysis targets single and multi-exon deletions/duplications; however, in some instances single exon resolution cannot be achieved due to isolated reduction in sequence coverage or inherent genomic complexity. Balanced structural rearrangements (such as translocations and inversions) may not be detected.

---

This test is not designed to detect low levels of mosaicism or to differentiate between somatic and germline variants. If there is a possibility that any detected variant is somatic, additional testing may be necessary to clarify the significance of results.

Genes may be added or removed based on updated clinical relevance. Refer to the [Targeted Genes and Methodology Details for Dilated Cardiomyopathy and Left Ventricular Noncompaction Cardiomyopathy Gene Panel](#) for the most up to date list of genes included in this test. For detailed information regarding gene specific performance and technical limitations, see Method Description or contact a laboratory genetic counselor.

If the patient has had an allogeneic hematopoietic stem cell transplant or a recent blood transfusion, results may be inaccurate due to the presence of donor DNA. Call Mayo Clinic Laboratories for instructions for testing patients who have received a bone marrow transplant.

#### Reclassification of Variants:

At this time, it is not standard practice for the laboratory to systematically review previously classified variants on a regular basis. The laboratory encourages healthcare providers to contact the laboratory at any time to learn how the classification of a particular variant may have changed over time.

#### Variant Evaluation:

Evaluation and categorization of variants are performed using published American College of Medical Genetics and Genomics and the Association for Molecular Pathology recommendations as a guideline.<sup>(4)</sup> Other gene-specific guidelines may also be considered. Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance. Variants classified as benign or likely benign are not reported.

Multiple in silico evaluation tools may be used to assist in the interpretation of these results. The accuracy of predictions made by in silico evaluation tools is highly dependent upon the data available for a given gene, and periodic updates to these tools may cause predictions to change over time. Results from in silico evaluation tools should be interpreted with caution and professional clinical judgment.

Rarely, incidental or secondary findings may implicate another predisposition or presence of active disease. Incidental findings may include, but are not limited to, results related to the sex chromosomes. These findings will be carefully reviewed to determine whether they will be reported.

#### Clinical Reference

1. Bozkurt B, Colvin M, Cook J, et al; American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; and Council on Quality of Care and Outcomes Research: Current diagnostic and treatment strategies for specific dilated cardiomyopathies: A scientific statement from the American Heart Association Circulation. 2016 Dec 6;134(23):e579-e646. doi: 10.1161/CIR.000000000000455. Erratum in: Circulation. 2016 Dec 6;134(23):e652
2. Ichida F: Left ventricular noncompaction-Risk stratification and genetic consideration. J Cardiol. 2020 Jan;75(1):1-9. doi: 10.1016/j.jcc.2019.09.011

---

3. Aung N, Doimo S, Ricci F, et al: Prognostic significance of left ventricular noncompaction: Systematic review and meta-analysis of observational studies. *Circ Cardiovasc Imaging*. 2020 Jan;13(1):e009712. doi: 10.1161/CIRCIMAGING.119.009712
4. Richards S, Aziz N, Bale S, et al: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015 May;17(5):405-424

## Performance

### Method Description

Next-generation sequencing (NGS) and/or Sanger sequencing is performed to test for the presence of variants in coding regions and intron/exon boundaries of the genes analyzed, as well as some other regions that have known disease-causing variants. The human genome reference GRCh37/hg19 build was used for sequence read alignment. At least 99% of the bases are covered at a read depth over 30X. Sensitivity is estimated at above 99% for single nucleotide variants, above 94% for deletions-insertions (delins) less than 40 base pairs (bp), above 95% for deletions up to 75 bp and insertions up to 47 bp. NGS and/or a polymerase chain reaction-based quantitative method is performed to test for the presence of deletions and duplications in the genes analyzed.

There may be regions of genes that cannot be effectively evaluated by sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high guanine-cytosine (GC) content, and repetitive sequences. See [Targeted Genes and Methodology Details for Dilated Cardiomyopathy and Left Ventricular Noncompaction Cardiomyopathy Gene Panel](#) for details regarding the targeted genes analyzed for each test and specific gene regions not routinely covered.(Unpublished Mayo method)

Confirmation of select reportable variants may be performed by alternate methodologies based on internal laboratory criteria.

Genes analyzed: *ABCC9, ACAD9, ACADVL, ACTC1, ACTN2, ALMS1, ALPK3, BAG3, CDH2, CPT2, CRYAB, CSRP3, DES, DMD, DNAJC19, DOLK, DSC2, DSG2, DSP, EMD, FKRP, FKTN, FLNC, GAA, GLA, HCN4, JPH2, JUP, LAMP2, LMNA, MYBPC3, MYH7, MYLK3, MYPN, NEXN, NKX2-5, PCCA, PCCB, PKP2, PLN, PPA2, PPCS, PRDM16, RAF1, RBM20, RYR2, SCN5A, SGCD, SHOC2, SLC22A5, TAZ (TAFazzin), TBX20, TCAP, TMEM43, TMEM70, TNNC1, TNNI3, TNNI3K, TNNT2, TPM1, TTN, TTR, and VCL*

### PDF Report

Supplemental

### Day(s) Performed

Varies

### Report Available

14 to 28 days

**Specimen Retention Time**

Whole blood: 2 weeks (if available); Extracted DNA: 3 months

**Performing Laboratory Location**

Mayo Clinic Laboratories - Rochester Main Campus

**Fees & Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

**Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

**CPT Code Information**

81439

**Prior Authorization**

Insurance preauthorization is available for this testing; forms are available.

Patient financial assistance may be available to those who qualify. Patients who receive a bill from Mayo Clinic Laboratories will receive information on eligibility and how to apply.

**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
DCLNG	Dilated Cardiomyopathy/LVNC Panel	107545-6

Result ID	Test Result Name	Result LOINC® Value
617240	Test Description	62364-5
617241	Specimen	31208-2
617242	Source	31208-2
617243	Result Summary	50397-9
617244	Result	82939-0
617245	Interpretation	69047-9
617246	Additional Results	82939-0
617247	Resources	99622-3
617248	Additional Information	48767-8

617249	Method	85069-3
617250	Genes Analyzed	48018-6
617251	Disclaimer	62364-5
617252	Released By	18771-6